Form 4: ALX Oncology's Chief Medical Officer Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Sophia Randolph, Chief Medical Officer of ALX Oncology Holdings Inc., sold shares of common stock on May 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 13, 2024, Sophia Randolph, the Chief Medical Officer of ALX Oncology Holdings Inc., sold shares of the company's common stock.
- The sales were executed under a Rule 10b5-1 trading plan adopted on January 11, 2024.
- A total of 10,203 shares were sold at a weighted average price of $15.8169, with individual prices ranging from $15.465 to $16.4602.
- An additional 1,797 shares were sold at a weighted average price of $16.6716, with individual prices ranging from $16.47 to $16.94.
- Following these transactions, Randolph directly owns 330,349 shares of ALX Oncology common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock sales under a pre-arranged trading plan, indicating a neutral sentiment.
Industry Context
Sales by company insiders are a common occurrence, and pre-planned sales under Rule 10b5-1 plans are often viewed as less impactful than discretionary sales.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market.
Key Dates
| Date | Description |
|---|---|
| 01/11/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 05/13/2024 | Date of stock sale transactions |
| 05/15/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.